Juvenile idiopathic arthritis often requires standardized and continuous treatment because it is a recurrent inflammatory disease that cannot be cured and therefore does not improve significantly in just a few years, and if necessary, requires lifelong treatment. Juvenile idiopathic arthritis is a common rheumatic disease in childhood, characterized by chronic synovitis with systemic damage to multiple organs. It is an important cause of disability or blindness in pediatrics. Typical clinical symptoms are fever, joint pain and rash. The polyarticular form usually involves ≥5 joints and is often symmetrical. The clinical symptoms of juvenile idiopathic arthritis are complex, and therefore need to be analyzed in conjunction with the patient’s clinical symptoms and relevant auxiliary examinations. Early detection, diagnosis and treatment can effectively prevent disability. After diagnosis, patients with juvenile idiopathic arthritis can take anti-rheumatic drugs such as methotrexate, hydroxychloroquine, etc., glucocorticosteroids such as methylprednisolone, prednisone, etc., and other immunosuppressants such as cyclosporine A, cyclophosphamide, etc., as prescribed by the doctor for treatment. Since the disease cannot be cured yet, but only slowed down, a few years of treatment is not enough to completely alleviate the disease, and lifelong treatment is needed if necessary. It is recommended that patients with juvenile idiopathic arthritis consult the rheumatology and immunology departments of regular hospitals in a timely manner and follow the doctor’s instructions for long-term standardized diagnosis and treatment.